within Pharmacolibrary.Drugs.V_Various.V08C_MagneticResonanceImagingContrastMedia.V08CB01_Ferumoxsil;

model Ferumoxsil
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 1,
    Cl = 0,
    adminDuration = 600,
    adminMass = 600 / 1000000,
    adminCount = 1,
    Vd = 0.001,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.016666666666666666,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Ferumoxsil</td></tr><tr><td>ATC code:</td><td>V08CB01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>600</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Ferumoxsil is an oral gastrointestinal contrast agent containing superparamagnetic iron oxide particles, formerly used to improve magnetic resonance imaging (MRI) of the gastrointestinal tract. It is not widely available or commonly used today, having been replaced by newer agents.</p><h4>Pharmacokinetics</h4><p>No published detailed pharmacokinetic (PK) parameters are available for ferumoxsil according to existing literature. Ferumoxsil is not systemically absorbed and acts locally in the gastrointestinal tract; its PK profile is consistent with negligible absorption in healthy adults.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.V.V08CB01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Ferumoxsil;
